All News
Does T2T Lead to Fewer Gout Flares?
Lancet Rheumatology reports that a treat-to-target (T2T) goal of average serum urate less than 6 mg/dL is associated with an absence of gout flares and a reduction in the number of flares in the next 12 months.
Read Article
SGLT2 Inhibitors in Type 2 Diabetes Lowers Gout Risk
A recent study of drugs used in type 2 diabetes (T2DM) shows that SGLT2 inhibitors have a lower risk for gout compared with those receiving DPP4 inhibitors.
Read Article
Genes and Obesity Tied to Higher Gout Risk in Women
Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.
Read Article
Day 4 Report from ACR21
My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.
Read Article
Why Are Physicians Silent About Outrageous Drug Prices?
https://t.co/hLrUFCiKwm https://t.co/ZgRoW9Duo6
Links:
Dr. John Cush RheumNow ( View Tweet)
COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients
 https://t.co/MrywKZKcIV https://t.co/QgajVPdesg
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA cohort study of 5.9 million VA pts and with & without gout ( 556 521)-gout pts had higher rates of lower extremity amputation (HR 1.59), than those without gout. This was assoc w/ poor uric acid control (>7), but not urate lowering therapy. https://t.co/KiM3IBCCp4
Links:
Dr. John Cush RheumNow ( View Tweet)
ASK CUSH ANYTHING!
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/7q5sMQuIHj https://t.co/ksCCvzdxka
Links:
Dr. John Cush RheumNow ( View Tweet)
Download your RheumaKnowledgy Card
https://t.co/GauMzCH5lB https://t.co/CrS7r6RAoc
Dr. John Cush RheumNow ( View Tweet)
Genes and Obesity Tied to Higher Gout Risk in Women
Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.
https://t.co/vLR8GJC9qf https://t.co/6Scc5c0dUU
Links:
Dr. John Cush RheumNow ( View Tweet)
ASK CUSH ANYTHING!
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/tl3Nkxdv0B https://t.co/WwxgWGuVcC
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR21 is complete--view all our RheumNow's coverage.
https://t.co/wkZ66lcB44
Links:
Dr. John Cush RheumNow ( View Tweet)
Geriatric Rheumatology:Improving care of aging patients
Dr.Kathryn Dao ( @KDAO2011) moderates a panel w/ Drs.Una Makris, Katherine Wysham, Sebastian Sattui + Devyani Misra, as they discuss aspects of improving care of/outcomes for aging patients. #ACR21
https://t.co/lF3yUZBEkd https://t.co/hYufA8ptqj
Links:
Dr. John Cush RheumNow ( View Tweet)
Data from ASN Kidney Wk 2021; US Renal Data System of 275,651 dialysis pts - 15% had gout Vs 85% without gout; Gout pts were older, more male, obese, had more hospitalizations (66 vs 57%), mortality, more CVD, PVD and MI https://t.co/m1d0SJEJjw
Links:
Dr. John Cush RheumNow ( View Tweet)
Gout being sneaky🧐
Common consult question is "infection or flare?" in patients with gout.
@ACR21 ABS0467 w/ Dr Michael Toprover:
🔸Calibrating DECT for LS-spine in gout patients.
🔹DECT signal = MSU deposition?
🔸Future data on back pain/gout flare/MSU🤞?
@RheumaRepublic https://t.co/aDCusqBk8G
Bonnia Liu bonnialiu ( View Tweet)
Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout flare when used in a T2T approach, with no differences in AEs, including CV risk. 99% achieved serum urate target over course of trial. Key slides following. #ACR21 https://t.co/tWeGvZ4rKY
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
We may be getting a new urate lowering therapy. Tigulixostat is a non-purine selective xanthine oxidase inhibitor. Nothing worrying on safety. But I think febuxostat is probably more effective than this? Abstr#L05 #ACR21 @RheumNow https://t.co/Lg0slMlah2
Richard Conway RichardPAConway ( View Tweet)
Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE events - I hope in long term less MACE due to less ⬆️CRP w flares. Modelling observational study abst#L06 #ACR21 #ACRBest @RheumNow below is comparative safety T2T better than usual care https://t.co/95M6lNX416
Janet Pope Janetbirdope ( View Tweet)
#ACR21 L05. Tigulixostat - non-purine selective XO inhibitor for gout
⭐️Effectively brought down serum uric acid <5, dose-dependent
⭐️10% pts gout flare with urate lowering
@Rheumnow https://t.co/LgwkAQ1wg8 https://t.co/G8CxdGcVOQ
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 L06 Comparative Safety of Gout "Treat-to-target" and "Usual Care" Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach https://t.co/4qo49lpBrt Video interview (https://t.co/k8PHCPaF1r) https://t.co/D4G2Ylkelm
Links:
Kazuki Yoshida kaz_yos ( View Tweet)
